This is a type of cancer that starts in the early stages of blood cell development, specifically lymphoid cells. It's the most common type of leukemia in children. The cancer cells, called lymphoblasts, grow uncontrollably in the bone marrow and can spread to other parts of the body like lymph nodes, skin, and bones. It usually presents as leukemia.
Every report comes from a Lived member, sent anonymously.
Have you tried Vincristine for Acute Lymphoblastic Leukemia (ALL)?
Acute lymphoblastic leukemia (ALL) is a fast-growing cancer of the blood and bone marrow, the soft tissue inside bones where blood cells are made. In ALL, the marrow produces large numbers of immature white blood cells called lymphoblasts. These cells never mature into working lymphocytes, the white blood cells that normally help fight infection, and as they multiply they crowd out the marrow's healthy output. The shortage of normal blood cells explains most symptoms. Too few red blood cells cause tiredness, weakness and pale skin. Too few platelets cause easy bruising, bleeding and petechiae (tiny flat red spots under the skin). Too few working white blood cells lead to frequent or lingering infections. Fever, bone or joint pain, painless swollen lymph nodes, and a feeling of fullness below the ribs as leukemia cells build up in the spleen or liver are also common. ALL is the most common cancer in children, diagnosed most often between ages 1 and 4, but it also occurs in adults. "Acute" means it usually worsens quickly if untreated, which is why treatment starts soon after diagnosis. Doctors classify ALL by the kind of lymphocyte involved (B cell or T cell) and by genetic changes in the leukemia cells, because both affect treatment. When the same disease mainly forms a mass, usually in the chest between the lungs, rather than filling the marrow, it is called lymphoblastic lymphoma and is treated in much the same way.
ALL begins when changes in the DNA of a developing blood cell let it keep dividing without maturing. In most people, the reason those changes happened is unknown, and they are not something a person or a child's parents could have foreseen or prevented. A few factors raise the risk. Certain inherited conditions make ALL more likely, most notably Down syndrome, along with rarer ones such as Li-Fraumeni syndrome, Fanconi anemia and neurofibromatosis type 1. Earlier chemotherapy or radiation therapy, exposure to high levels of radiation, and x-ray exposure before birth are other recognized factors, and ALL is somewhat more common in males. Most people with a risk factor never develop ALL, and most people who develop it have no known risk factor. When a child's medical or family history raises the question of an inherited cause, genetic counseling can help a family decide whether testing makes sense and what it would mean for siblings.
ALL is usually first suspected from a complete blood count (CBC), a routine blood test that counts red blood cells, white blood cells and platelets. Low red cell or platelet counts, an unusually high or low white cell count, and immature blast cells seen when the blood is examined under a microscope all point toward leukemia, but a blood test alone does not confirm it. The diagnosis is confirmed with a bone marrow aspiration and biopsy. After the skin is numbed, a hollow needle removes a small sample of liquid marrow and bone, usually from the hip bone. Laboratory tests on that sample then shape treatment. Immunophenotyping, which reads markers on the surface of the cells, shows whether the leukemia arose from B cells or T cells. Genetic tests look for chromosome changes, such as the Philadelphia chromosome, in which pieces of chromosomes 9 and 22 trade places and create an abnormal gene called BCR::ABL1. Finding it changes treatment. A lumbar puncture (spinal tap) collects a sample of the fluid around the brain and spinal cord, because leukemia cells can spread and hide there. A chest x-ray looks for a mass in the chest. In children, age and the white blood cell count at diagnosis, together with these results, place a child in a risk group: standard risk generally means ages 1 to 9 with a white count below 50,000 per microliter, while infants, older children, higher counts and certain genetic changes mean high or very high risk. Marrow tests repeated during treatment show how quickly and how completely the leukemia cells disappear, which can move a person into a different risk group.
Treatment for ALL is intensive, long and given in phases. The first phase, induction, lasts about a month and uses a combination of chemotherapy drugs, often including a steroid such as prednisone or dexamethasone, to bring about remission: normal blood counts and no leukemia detectable by standard tests. In adults, 60% to 80% reach complete remission after induction. Consolidation (also called intensification) then uses further chemotherapy to destroy leukemia cells that tests can no longer see but that could regrow. Maintenance follows with lower doses of chemotherapy and, in children, generally continues for two to three years. Throughout, chemotherapy is also given directly into the spinal fluid (intrathecal chemotherapy), sometimes with radiation to the brain, because many drugs given by mouth or vein do not reach leukemia cells around the brain and spinal cord. The plan is matched to the leukemia's features. Children in higher risk groups, teenagers and young adults, and people with T-cell ALL receive more drugs and higher doses. For Philadelphia chromosome-positive ALL, a targeted pill that blocks the abnormal BCR::ABL1 signal, such as imatinib (Gleevec) or dasatinib (Sprycel), is added to chemotherapy. This subtype was rarely cured with chemotherapy alone, and long-term survival is now commonly reported with the combination. Immune-based treatments are used mainly for B-cell ALL that does not respond, returns, or leaves small amounts of leukemia behind. Blinatumomab (Blincyto) is an antibody that links a person's own T cells, a type of immune cell, to the leukemia cells so the T cells can kill them; it is also used during consolidation for some newly diagnosed people. CAR T-cell therapy (CAR stands for chimeric antigen receptor) reprograms a person's own T cells in a laboratory to attack the leukemia: tisagenlecleucel (Kymriah) is used for people up to age 25 whose B-cell ALL has not responded or has returned more than once, and related products, such as brexucabtagene autoleucel (Tecartus), are used in adults whose B-cell ALL has not responded or has returned. Both kinds of treatment can trigger a strong immune reaction called cytokine release syndrome (fever and low blood pressure among its signs) and confusion or other nervous system effects, so they start under close monitoring by an experienced team. A stem cell transplant from a donor replaces the blood-forming system after high-dose chemotherapy, often with whole-body radiation, and the donor's immune cells may also attack leukemia cells left behind. It is rarely part of first treatment for children and adolescents but is used after relapse or a poor response, and for some adults while in remission. Its potential to cure is weighed against substantial risks, the person's age and overall health. Supportive care runs alongside every phase: antibiotics to prevent and treat infections, and red blood cell and platelet transfusions while counts are low. Clinical trials testing new treatments or new ways of using current ones are an option worth asking about at diagnosis and at relapse.
The first weeks after diagnosis are usually the most demanding, with frequent hospital or clinic visits, blood tests, transfusions, repeated lumbar punctures and marrow tests. Because both the leukemia and its treatment lower the number of infection-fighting white blood cells, serious infection is the most immediate risk during treatment, and the care team will explain how to watch for it. Which other side effects appear depends on the drugs and doses used, and the team can explain what to look for and how each is managed. Treatment is long. In children, maintenance generally continues for two to three years, with regular blood tests to check counts and adjust doses. Taking maintenance medicine exactly as directed matters: missed doses increase the chance that the leukemia comes back. Outlook depends strongly on age and on the leukemia's biology. About 90% of children younger than 15 now survive at least five years, and treatment gives children a good chance of cure. For teenagers aged 15 to 19 the five-year figure is above 75%. Adults generally face a harder course, especially at older ages and with Philadelphia chromosome-positive disease, although targeted pills and immune-based treatments have improved results. How quickly and how completely the leukemia clears after the first month of treatment is one of the most important signs of how things will go. If ALL returns, it can come back in the marrow, the brain and spinal cord, or the testicles, and further treatment is often still possible, though results depend on when and where it returns. Follow-up continues for years after treatment ends. Late effects can appear months or years later and may include problems with the heart, blood vessels, liver, bones or fertility; changes in learning, memory or mood (more likely in children who had brain radiation before age 4); and second cancers. Regular follow-up visits help find and manage these early.
Arrange a prompt doctor visit for ongoing tiredness or paleness, unexplained bruising or bleeding, tiny red spots on the skin, infections that keep returning or will not clear, fever or drenching night sweats without a clear cause, bone or joint pain, or painless lumps in the neck, armpit or groin. These usually have other explanations, but a blood count is a quick way to check. New, mild or slowly developing trouble breathing, wheezing, difficulty swallowing, or swelling of the face, neck or upper body can come from a mass in the chest and should be checked by a doctor promptly. Breathing that is hard or getting worse, breathing trouble that worsens when lying flat, or swelling of the face and neck that grows quickly needs emergency care right away (call 911), because a large chest mass can press on the windpipe or on the large vein that drains blood from the head. During treatment, call the care team right away, at any hour, for a temperature of 100.5°F (38°C) or higher (or the threshold your team gives you), chills, or redness or swelling where a catheter enters the body, because an infection during treatment can be life threatening. Check with the team before taking a fever reducer such as acetaminophen (Tylenol) or ibuprofen (Advil), since it can hide a fever.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Acute Lymphoblastic Leukemia (ALL) is like, what's helped you, or ask the community a question.